Key facts
- This page summarizes Christopher Mutz's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2023, 20:07.
Christopher Mutz - 28 Feb 2023 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)
- Reporting relationship
- HEAD OF RARE DISEASE
- Issuer ticker
- ANIP
- Reported as of
- 28 Feb 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2023, 20:07:28 UTC
- Prior SEC filing
- 17 Feb 2023
- Next SEC filing
- 09 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Mutz filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 04 Apr 2023.
Change
- Previous filing in this sequence was filed on 17 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ANIP
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +17,369
- Change %
- +46%
- Price
- $0.000000
- Shares after
- 55,029
- Date
- 28 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
ANIP
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +11,578
- Change %
- +21%
- Price
- $0.000000
- Shares after
- 66,607
- Date
- 28 Feb 2023
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a restricted stock award that will vest in four equal annual installments on the first, second, third and fourth anniversaries of February 28, 2023.
Footnote F2
These shares represent performance stock units, which will vest over the applicable performance period based on the achievement of the provided performance targets, as set forth in the governing award agreement, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.
SEC remarks
Exhibit-24 - Power of Attorney